STADA completed the acquisition of Takeda’s OTC portfolio in Russia/CIS for $660m.

STADA Arzneimittel, a pharmaceutical company, completed the acquisition of a portfolio of approximately 20 selected over-the-counter and prescription pharmaceutical assets sold inter alia in Russia, Georgia, Azerbaijan, Belarus, Kazakhstan, and Uzbekistan from Takeda Pharmaceutical for a total value of $660m. "This is STADA’s largest acquisition to date and will position us as a major player in a large and structurally growing market. This transaction also reflects the ambitions of STADA as we continue expanding the business internationally - both organically and through acquisitions - and continue generating significant operating efficiencies worldwide. STADA’s branded products are already well-represented in the most popular pharmacy categories in our key markets. However, we are continuing to expand our portfolio of branded generics, to strengthen our position in strategic niches and to develop new market segments," Peter Goldschmidt, STADA CEO.